Zeptosens finds way to CHF 14 million

Investee Company – Zeptosens AG

Investee Company Country – Switzerland

Investee Company Business Type – Develops bioanalytical solutions

Type of Financing – Development

Equity Providers – TVM Techno Venture Management, Swiss Life Private Equity Partners

Equity Leader (Individual) – Dr Alexandra Goll, TVM Techno Venture Management

Debt Providers – N/A

Debt Type – N/A

Debt Leader (Individual) – N/A

Equity Amount – CHF14 million

Total Deal Value – CHF14 million

Other Advisors – N/A

Comments – Bioanalytical solutions company, Zeptosens AG, has completed a CHF14 million (euro9.1 million) financing round. TVM Techno Venture Management lead the deal which included Swiss Life Private Equity.

Based in the Rhine “biovalley” of Switzerland, Zeptosens AG focuses its activity on the development of bioanalytical solutions. The founding of the company in September 1998 by a leading team of experts from Novartis Pharma AG, led to the invention of a unique bioaffinity interaction analysis system based on planar waveguide detection technology.

Plans for the new equity involve the propagation of the company’s development and production programme for its proprietary microarray readout system, ZeptoREADER, and will also help to initiate the development of the ZeptoGENE DNA and the ZeptoMARK protein microarray product group.

The investment also heralded the appointment of Dr Alexandra Goll, partner at TVM, to the board of directors of Zeptosens AG.